Phaseline

Targets › TL1A

TL1A (Tumor necrosis factor ligand superfamily member 15): drug programs, companies and trials

3 programs from 3 companies in 11 trials: 6 Phase 2, 3 Phase 3, 2 Phase 1; Immunology, Other; next expected readout Jan 2027.

Cytokine that signals through TNFRSF25 receptor. Functions as a T-cell costimulator, that increases IL-2 responsiveness and secretion of pro-inflammatory cytokines which enhances T-cell activation, proliferation and the survival of activated T-cells. (UniProt, O95150)

Open in Phaseline: the race on TL1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck & Co. (MSD)Tulisokibart
Humanized monoclonal antibody that binds tumor necrosis factor-like cytokine 1A (TL1A)
TL1APhase 3Crohn's Disease; Ulcerative Colitis; Crohn Disease; Psoriatic Arthritis …Feb 2027
BiocadBCD-261
Anti-TL1A human monoclonal antibody
TNFSF15, TL1APhase 2Ulcerative Colitis (UC); Crohn's Disease (CD); HealthyJan 2027
SPH-BIOCAD (HK)BCD-261
anti-TL1A human monoclonal antibody
TL1APhase 1Healthy Adult ParticipantsMar 2027

Conditions

Ulcerative Colitis (UC) (1) Crohn's Disease (CD) (1) Healthy (1) Crohn's Disease (1) Ulcerative Colitis (1) Crohn Disease (1) Psoriatic Arthritis (1) Radiographic Axial Spondyloarthritis (1) Hidradenitis Suppurativa (1) Arthritis, Rheumatoid (1) Healthy Adult Participants (1)

Modalities

small molecule (2), antibody (1)

Companies

Biocad (1) Merck & Co. (MSD) (1) SPH-BIOCAD (HK) (1)

Related targets

TNFSF15 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.